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OBJECTIVES: Literature on epidemiology of vulvar and
vaginal cancers is scarce. It has been reported that about 40%
of vulvar and 70% of vaginal cancers may be linked to human
papillomavirus (HPV). This study aimed to assess the economic
burden of vulvar and vaginal cancer and lesions in France.
METHODS: A retrospective analysis using the French hospital
database (PMSI), in which all admissions to public and private
hospitals are recorded, was performed to assess the annual
number of hospitalised patients and associated management
cost from the health care payer perspective (French Social Secu-
rity System). Admissions in 2006 for vulvar and vaginal cancers
and precancerous lesions were extracted. Radiotherapy sessions
performed in the private sector are not reported in the PMSI
and were estimated from SAE database. The mean charges for
the payer were estimated from 2007 ofﬁcial DRG (diagnosis
related group) tariffs for public and private hospitals. Outpa-
tient and daily allowance costs (paid by the health care payer)
were based on literature review. RESULTS: In 2006, the
number of hospitalised patients was estimated at 1237 and 623
for vulvar cancer and lesions and at 728 and 244 for vaginal
cancer and lesions, respectively. Annual hospital costs were esti-
mated at €5.7 million and €980,158 for vulvar cancer and
lesions and €4.0 million and €312,244 for vaginal cancer and
lesions, respectively. Adding outpatient and daily allowance
costs led to a total cost of €9.4 million and €6.7 million for,
respectively, vulvar and vaginal cancer. CONCLUSIONS: The
burden of vulvar and vaginal diseases appears to be substantial.
As the HPV6/11/16/18 vaccine is indicated for the prevention
of vaccine type-related precancerous vulvar and vaginal lesions,
these data could provide useful information for decision-
makers. Further research is needed to assess the outpatient
burden of precancerous lesions which may be mostly managed
in an outpatient setting.
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OBJECTIVES: MBD secondary to cancer can result in serious
and costly SREs. The objective of this study was to characterise
hospital burden associated with MBD and SREs following BC
and PC in Spain. METHODS: Data from IASIST’s Conjunto
Mínimo Básico Datos (CMBD) hospital activity database
(January 1, 2000–March 31, 2006) were analysed. The CMBD
database contains clinical and administrative data on hospital
admissions at 187 public and private hospitals in Spain. Patients
with an index inpatient admission of female BC or PC (ICD-9
codes 174* and 185* respectively) between January 1, 2003 and
December 31, 2003 were selected for analysis and followed until
March 31, 2006 for subsequent admissions inclusive of MBD
(ICD-9 198.5 or ICD-10 C79.5) and SREs (pathological frac-
tures, spinal cord compressions, bone surgery). Hospital length
of stay (LOS) and inpatient costs were analysed by cancer type
(BC or PC) and disease stage (index, MBD, or SRE). RESULTS:
A total of 10,090 patients were identiﬁed with BC and 7546 with
PC. The 3-year incidence rates/1000 hospital admissions, includ-
ing MBD diagnosis code and MBD&SRE diagnosis codes, were
94.7 and 20.0 for BC and 166.0 and 29.3 for PC. Readmissions
were consistent across both cancer types, with MBD + SRE
patients having the greatest number of readmissions (BC: 66%;
PC: 62%) compared to patients with cancer diagnosis only (BC:
32%; PC: 27%) and patients with cancer & MBD (BC: 58%; PC:
54%). Additionally, patients developing MBD & SREs had
greater mean total LOS (BC: 28 days; PC: 32 days) than those
with cancer only (BC: 8 days; PC: 15 days), and those with
cancer & MBD (BC: 18 days; PC: 22 days). Mean cost of
admissions increased as the disease progressed from cancer only
to MBD&SREs for BC and PC patients (€2374 to €3757 and
€3194 to €3585, respectively). CONCLUSIONS: In general,
Spanish patients with BC and PC, who develop SREs secondary
to MBD consume greater hospital resources than those with
cancer or MBD only.
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OBJECTIVES: To assess the resource utilization and direct
medical costs associated with palliative care for cancer patients in
Brazil under the private payer and the patient perspective.
METHODS: The target population consisted of adult patients
diagnosed with cancer under palliative care. A modiﬁed Delphi
panel validated and supplemented international published data,
and estimated standard treatment patterns in Brazil. The study
included only direct medical costs for managing pain, dyspnea,
depression and other complications during hospitalization, home
care or ambulatory care. The time horizon was six months, due
to the short survival of patients under palliative care. RESULTS:
During palliative care, 2% of patients needed hospitalization in
the Intensive Care Unit and 18% in a general ward; 28% were
under home care and 52% under ambulatory care. Total
weighted average direct medical costs for six months were
R$13,108 (US$8,091) per patient, of which R$8,964 (US$5,533)
were reimbursed by the private payer and R$4,144 (US$2,558)
were out-of-pocket expenses for the patient. Considering total
costs of care, the treatment of pain, dyspnea and depression
represented 19%, 14% and 10% of total costs respectively. Hos-
pitalization and home care were the major cost items, accounting
for 43% of total costs. Under the private payer perspective, these
same percentages were 4%, 16%, 0% and 63%, respectively.
Under the patients’ perspective the percentages were 51%, 11%,
32% and 0%. These differences highlight the fact that medica-
tion is only reimbursed when used during hospitalization. CON-
CLUSIONS: Palliative care is becoming a relevant ﬁeld of study
in Brazil recently. This cost of illness study estimated an average
cost of patients in six months under palliative care of R$13,108,
considering both private payer’s and patients’ out-of-pocket
costs. For the private payers the main cost item was
hospitalization/home care and for patients it was the treatment of
pain.
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OBJECTIVES: To assess the current management and resource
use, and the associated costs from the perspective of the Belgian
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